[1] |
Horiike A,Kimura H,Nishio K, et al. Detection of epidermal growth factor receptor mutation in transbronchial Needle Aspirates of Non-Small Cell Lung Cancer[J]. Chest, 2007,131(6):1628-1634.
|
[2] |
Kimura H,Suminoe M,Kasahara K, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib(IRESSA)[J]. Br J Cancer, 2007,97(6):778-784.
|
[3] |
Yohe S,Thyagarajan B. Review of clinical next-generation sequencing[J]. Arch Pathol Lab Med, 2017,141(11):1544.
|
[4] |
Bianchi DW,Parker RL,Wentworth J, et al. DNA sequencing versus standard prenatal aneuploidy screening[J]. N Engl J Med, 2014,370(9):799-808.
|
[5] |
Liao C,Yin AH,Peng CF, et al. Noninvasive prenatal diagnosis of common aneuploidies by semiconductor sequencing[J]. Proc Natl Acad Sci USA, 2014,111(20):7415-7420.
|
[6] |
Kuderer NM,Burton KA,Blau S, et al. Comparison of 2 commercially available next-generation sequencing platforms in Oncology[J]. JAMA oncol, 2017,3(7):996-998.
|
[7] |
Balmana J,Digiovanni L,Gaddam P, et al. Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing[J]. J Clin Oncol, 2016,34(34):4071-4078.
|
[8] |
Torga G,Pienta KJ. Patient-paired sample congruence between 2 commercial liquid biopsy tests[J]. JAMA Oncol, 2017. [Epub ahead of print]
|
[9] |
宋昊岚,胥劲,周君. 质量改进方案在临床实验室的实施[J]. 检验医学, 2006,21(4):429-431.
|
[10] |
申子瑜,李金明. 临床基因扩增检验技术[M]. 北京:人民卫生出版社, 2012:136-160.
|
[11] |
Leighl NB,Rekhtman N,Biermann WA, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline[J]. J Clin Oncol, 2014,32(32):3673-3679.
|
[12] |
江佳佳,李晓华. 临床基因扩增检测的全面质量管理[J/CD].中华临床实验室管理电子杂志, 2017,5(4):251-254.
|
[13] |
Cree IA,Zandra D,Ligtenberg M, et al. Guidance for laboratories performing molecular pathology for cancer patients[J]. J Clin Pathol, 2014,67:923-931.
|
[14] |
齐妍,常彬,李锋. 组织固定对核酸含量及完整性的影响[J]. 临床与病理杂志, 2006,26(3):269-272.
|
[15] |
Douillard J,Ostoros G,Cobo M, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study[J]. Br J Cancer, 2014,110(1):55-62.
|
[16] |
张杰. 肺癌治疗靶向基因研究进展及临床分子病理检测[J]. 上海交通大学学报, 2013,33(10):1315-1322.
|
[17] |
姜伯玮,赵兴春,姜成涛,等. Qubit®快速荧光定量系统在法医学中的应用[J]. 证据科学, 2009,17(1):123-128.
|
[18] |
蔡旭,张太明,陆永明,等. 病理科PCR实验室的质量管理与控制[J].临床与实验病理学杂志, 2011,27(4):419-420.
|
[19] |
临床分子病理实验室二代基因测序检测专家共识编写组. 临床分子病理实验室二代基因测序检测专家共识[J]. 中华病理学杂志, 2017,46(3):145-148.
|
[20] |
李金明. 实时荧光PCR技术[M]. 北京:科学出版社, 2016:30-62.
|
[21] |
康凤凤,王治国. ISO 15189:2012与临床检验定量检测方法确认和性能验证[J].临床检验杂志, 2013,31(12):881-884.
|
[22] |
徐建辉,王惠民,苏建友,等. 商品定量试剂盒分析性能的验证试验[J].临床检验杂志, 2010,28(5):378-379.
|
[23] |
陈德建. 谈质量控制与质量保证的区别[J]. 黎明职业大学学报, 2003,(2):60-63.
|